NIKKEI 225
38,175.49 +101.51 (+0.27%) HANG SENG
18,859.60 +321.79 (+1.74%) CRUDE OIL
79.78 +0.52 (+0.66%) GOLD FUTURES
2,358.20 +17.90 (+0.76%) DOW
39,387.76 +331.36 (+0.85%) Bitcoin GBP
50,324.34 +1,171.93 (+2.38%)
Caribou Biosciences, Inc. (CRBU)
After hours:
| Previous close | 3.5000 |
| Open | 3.5000 |
| Bid | 3.6400 x 600 |
| Ask | 3.6700 x 100 |
| Day's range | 3.5000 - 3.6950 |
| 52-week range | 3.4400 - 8.5900 |
| Volume | |
| Avg. volume | 1,642,914 |
| Market cap | 329.66M |
| Beta (5Y monthly) | 2.56 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Caribou Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update
-- Advancing CB-010 ANTLER Phase 1 trial in 2L LBCL; initial dose expansion data to be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting -- -- Expanding into autoimmune diseases with IND cleared for CB-010 in lupus nephritis and extrarenal lupus; GALLOP Phase 1 clinical trial expected to initiate by YE 2024 -- -- Advancing four clinical-stage programs for hematologic malignancies and autoimmune diseases; multiple milestones ahead -- -- $345.9 million in cash, cash
- GlobeNewswire
Caribou Biosciences to Participate in Upcoming Investor Conferences
BERKELEY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the company’s participation in the following investor conferences: 2024 RBC Capital Markets Global Healthcare Conference, New York, NYMay 14, 2024, fireside chat at 3:35 pm EDTWebcast BofA Securities 2024 Health Care Conference, Las Vegas, NVMay 15, 2024, corporate presentation at 3:40 pm PDTWebcast For more informa
- GlobeNewswire
Caribou Biosciences to Present Initial Dose Expansion Data from CB-010 ANTLER Phase 1 Trial in r/r B-NHL at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
BERKELEY, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced two abstracts have been accepted for poster presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held May 31-June 4, 2024 in Chicago, Illinois. The ANTLER poster will provide initial dose expansion data. Details of the poster presentation are as follows: Title: A CRI
